Recently, by taking advantage of cutting-edge tumor immunology, scientists have developed novel drugs targeted at ICIs for treating solid tumors, and a few products targeted at CTLA4 and PD-1 have been put into clinical practice. The gene discussed is CTLA4; the disease is neoplasm.